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Of 462 Korean Clostridium difficile isolates, 77.5% were toxin B positive but 21.4% were toxin A negative (A
B). The binary toxin gene was detected in nine isolates. A higher fluoroquinolone resistance of A B strains
may contribute to the increase of these strains. Toxin A detection alone may underdiagnose C. difficile-
associated disease.
Clostridium difficile-associated disease (CDAD) is due to
strains producing toxins A (enterotoxin) and B (cytotoxin),
which are encoded by tcdA and tcdB, respectively (4, 5). Toxin
A-negative, toxin B-positive (A B) strains of C. difficile,
described in the early 1990s (3), have been increasingly re-
ported in some parts of the world (6, 15). A B strains fail to
produce toxin A due to deletion of the repetitive domain of the
tcdA gene but can cause CDAD, including fatal pseudomem-
branous colitis (15). Some C. difficile strains also produce bi-
nary toxin (actin-specific ADP-ribosyltransferase [CDT]),
which contributes to CDAD. Two genes, cdtA and cdtB, en-
code the enzymatic and binding components of the toxin (14).
Clindamycin in the 1970s and cephalosporins in the late
1980s and through the 1990s were the antimicrobial agents
associated with the highest relative risk of CDAD (7). How-
ever, more recently, outbreaks of CDAD due to a new binary
toxin-producing (CDT) strain (pulsed-field gel electrophore-
sis type NAP1, PCR ribotype 027) with high morbidity and
mortality have been reported in Canada, the United States,
and Europe. This epidemic strain showed increased resistance
to fluoroquinolones (11), suggesting that fluoroquinolone use
was a risk factor in these outbreaks.
Laboratory diagnosis of CDAD includes detecting cytotoxin
and/or toxin A and toxin B proteins (1). Besides direct toxin
assay from stool specimens, toxigenic C. difficile culture is rec-
ommended to improve the diagnosis. The presence of A B
strains may profoundly affect the diagnosis of CDAD, depend-
ing on the kinds of tests used, but the prevalence of this type of
strain in Korea is not well known.
The aim of this study was to determine the prevalence of A
B isolates and the presence of CDT strains of C. difficile in
Korea. The susceptibility to fluoroquinolones was also deter-
mined.
The C. difficile strains were isolated between 1980 and 2006
from stool specimens of suspected CDAD patients at a tertiary
care hospital in Korea. Cycloserine-cefoxitin-fructose agar was
used for the isolation (1), and the isolates were identified by
using conventional tests and the ATB 32A system (bioMerieux,
Marcy-l’Etoile, France). The control C. difficile strains, VPI
10463 (A B), 3608/03 (A B), 1470 (A B), and SE844
(CDT), were obtained from Maja Rupnik in Slovenia. Strain
NAP1/027 was provided by one of the authors of the present
report (T. V. Riley).
C. difficile toxin genes were detected by PCR as described
previously (17). The primer pairs used were NK2-NK3 for
tcdA, NK9-NK11 for the repetitive domain of tcdA, NK104-
NK105 for tcdB, cdtA pos-cdtA rev for cdtA, and cdtB pos-
cdtB rev for cdtB. PCR ribotyping was performed as described
previously (13).
The antimicrobial susceptibilities were determined by the
National Committee for Clinical Laboratory Standards-recom-
mended agar dilution method (12), using norfloxacin, cipro-
floxacin, ofloxacin, and levofloxacin (Sigma-Aldridge, St.
Louis, MO), gatifloxacin (Grunenthal, Aachen, Germany), and
moxifloxacin (Bayer, Wuppertal, Germany).
Of the 462 isolates tested, 358 (77.5%) were either A B
(259; 56.1%) or A B (99; 21.4%). A B strains, which were
first detected in 1995 in samples from two patients, steadily
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TABLE 1. Toxigenic status of Korean C. difficile strains by year
of isolation
Year of isolation
(no. of isolates
tested)
No. (%) of isolates with toxin status
A B
CDT
A B
CDT
A B
CDT
A B
CDT
1980 (3) 2 (66.7) 0 (0.0) 0 (0.0) 1 (33.4)
1990 (12) 9 (75.0) 0 (0.0) 0 (0.0) 3 (25.0)
1995 (48) 34 (70.8) 1 (2.1) 2 (4.2) 11 (22.9)
2002 (46) 28 (60.9) 0 (0.0) 6 (13.0) 12 (26.1)
2003 (105) 67 (63.8) 0 (0.0) 16 (15.2) 22 (21.0)
2004 (53) 22 (41.5) 1 (1.9) 21 (39.6) 9 (17.0)
2005 (40) 15 (37.5) 1 (2.5) 12 (30.0) 12 (30.0)
2006 (155) 73 (47.1) 6 (3.9) 42 (27.1) 34 (21.9)
Total (462) 250 (54.1) 9 (2.0) 99 (21.4) 104 (22.5)
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increased thereafter (Table 1). All our PCR detection of the
repetitive domains of tcdA and of tcdB was accurate compared
with the results of C. difficile Tox-A enzyme-linked immunosor-
bent assay (TechLab, Blacksburg, VA) and a Vero cell cyto-
toxicity assay with antitoxin (TechLab).
In another Korean study in 2004, the proportion of A B
strains was even higher, i.e., 45.7% of 81 isolates (16). These
results documented that A B strains are much more prev-
alent in Korea than in other countries, i.e., 0% to 12.5% (2, 10,
17), and indicated that there is a potential for underdiagnosis
of CDAD when the toxin A test alone is used for the diagnosis.
Because of a significant increase in A B strains in 2002,
187 strains isolated between August 2002 and May 2004 were
tested for PCR ribotype and for antimicrobial susceptibility.
Overall, 39 PCR ribotypes were identified: 115 A B isolates
comprised 22 ribotypes, and the most-common type accounted
for 62 (33%) isolates; all 31 A B strains showed the same
pattern, which was identical to that of strain 1470 (ribotype
017). The majority of A B strains gave this distinct ribotype
pattern in many studies, suggesting their clonal spread world-
wide (2, 6, 15).
Only nine of our isolates (2.0%) were CDT, i.e., PCR
positive for the cdtA and cdtB genes. However, six of nine
CDT strains were isolated in 2006, suggesting a gradual in-
crease of this toxin type for which continuous study is required.
The prevalence of CDT strains has been reported to be 1.6%
in Asia (15), 5.8% in the United States (8), and 6% in France
(9). The nine CDT strains revealed four ribotypes which were
different from that of the epidemic PCR ribotype 027 strain.
Overall, the MICs of fluoroquinolones were slightly lower
for the nontoxigenic strains and slightly higher for A B
strains in comparison to their MICs in A B strains (Table 2).
The MICs of gatifloxacin and moxifloxacin were higher for the
A B strains than for the A B strains. Drudy et al. (6)
reported that A B strains isolated during an outbreak
showed high-level resistance to fluoroquinolones and consid-
ered that this may be a factor promoting outbreaks in hospitals.
We require a further study to determine if the risk factor for
increasing CDAD due to A B strains is indeed the use of
fluoroquinolones.
In conclusion, testing for both toxin A and toxin B became
very important for the accurate laboratory diagnosis and epi-
demiologic study of CDAD with the increasing prevalence of
A B strains in Korea. CDT strains have emerged in Korea,
although the ribotype 027 strain was not found.
This study was supported by a faculty research grant from Yonsei
University College of Medicine for 2006 (grant 6-2006-0073).
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TABLE 2. In vitro activities of fluoroquinolones against 187
Korean C. difficile isolates according to toxigenic status
Toxin status
(no. of isolates tested)
Antimicrobial
agent
MIC (g/ml)
Range MIC50 MIC90
A B (115) Norfloxacin 16–256 64 128
Ciprofloxacin 4–128 16 32
Ofloxacin 8–256 64 128
Levofloxacin 2–128 32 64
Gatifloxacin 1–32 8 8
Moxifloxacin 1–16 8 8
A B (31) Norfloxacin 32–128 64 128
Ciprofloxacin 8–64 32 32
Ofloxacin 8–256 128 256
Levofloxacin 4–128 64 128
Gatifloxacin 1–32 32 32
Moxifloxacin 1–32 32 32
A B (41) Norfloxacin 32–128 32 64
Ciprofloxacin 4–32 8 8
Ofloxacin 8–256 8 8
Levofloxacin 4–128 4 4
Gatifloxacin 1–32 1 2
Moxifloxacin 1–16 1 2
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